These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. Upadya S; Lee FA; Saldarriaga C; Verma S; Sedrakyan A; Nystrom K; Katz SD J Heart Lung Transplant; 2004 Apr; 23(4):466-72. PubMed ID: 15063407 [TBL] [Abstract][Full Text] [Related]
8. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Gorodeski EZ; Chu EC; Reese JR; Shishehbor MH; Hsich E; Starling RC Circ Heart Fail; 2009 Jul; 2(4):320-4. PubMed ID: 19808355 [TBL] [Abstract][Full Text] [Related]
9. [Dobutamine therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in severe heart failure]. Brügemann J; de Jonge-Weber AT; Rienstra M; van den Broek SA; Zijlstra F; van Veldhuisen DJ Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2460-5. PubMed ID: 18064867 [TBL] [Abstract][Full Text] [Related]
10. Continuous Intravenous Milrinone Therapy in Pediatric Outpatients. Curley M; Liebers J; Maynard R J Infus Nurs; 2017; 40(2):92-96. PubMed ID: 28248808 [TBL] [Abstract][Full Text] [Related]
11. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes. López-Candales AL; Carron C; Schwartz J Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852 [TBL] [Abstract][Full Text] [Related]
12. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447 [TBL] [Abstract][Full Text] [Related]
13. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729 [TBL] [Abstract][Full Text] [Related]
14. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Kurien S; Warfield KT; Wood CM; Miller WL Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223 [TBL] [Abstract][Full Text] [Related]
15. [Infusion of inotropic agents at home in patients with severe heart failure: an important role for the nurse practitioner]. Ypenburg C; Verwey HF; van der Wall EE Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2426-8. PubMed ID: 18064859 [TBL] [Abstract][Full Text] [Related]
16. Outpatient dobutamine for end-stage congestive heart failure. Miller LW; Merkle EJ; Herrmann V Crit Care Med; 1990 Jan; 18(1 Pt 2):S30-3. PubMed ID: 2293976 [TBL] [Abstract][Full Text] [Related]
17. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Bayram M; De Luca L; Massie MB; Gheorghiade M Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823 [TBL] [Abstract][Full Text] [Related]
19. Should we use outpatient dobutamine or milrinone? Kato M; Sanada S; Kitakaze M Circ Heart Fail; 2009 Jul; 2(4):377-8. PubMed ID: 19808362 [No Abstract] [Full Text] [Related]